Dr. Lillian Gill, who had been deputy director, has been named director of the independent, non-profit panel of scientific and medical experts that assesses the safety of cosmetic ingredients used in the US market.
Andersen joined the US Food and Drug Administration (FDA) in 1971 as a researcher studying the genotoxic effects of radiation after completing his Ph.D. in Biophysics at Penn State. After more than 22 years in numerous leadership roles at the FDA, he joined the CIR as Director.
Andersen is a past president of Clinical and Laboratory Standards Institute (CLSI), an organization promoting the development and use of voluntary consensus standards and guidelines for clinical testing.
“Dr. Andersen’s tenure on the CIR Panel spans 20 of the 36 years since its conception and due to his commitment and diligence, CIR has been a dominant force in assuring public safety of cosmetic ingredients,” said Dr. Wilma F. Bergfeld, chair, CIR Panel. “On Alan’s watch, he expanded the panel to include more experts with strong backgrounds in chemistry, toxicology, scientific research, as well as skilled professionals that advanced and introduced new technologies.”
Gill had served as deputy director since 2011. Prior to joining the CIR, she served as the senior associate director of the FDA’s Center for Devices and Radiological Health (CDRH) and was a member of the senior executive service.